PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly

This study has been completed.
Sponsor:
Information provided by:
Somerset Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00532116
First received: September 18, 2007
Last updated: NA
Last verified: September 2007
History: No changes posted
  Purpose

Evaluate the effect of age on the PK of two different doses of EMSAM.


Condition Intervention Phase
Healthy
Drug: EMSAM (Selegiline Transdermal System) 6mg
Drug: EMSAM (Selegiline Transdermal System) 12mg
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Pharmacokinetic Comparison of the 6mg/24hr and 12mg/24hr EMSAM (Selegiline Transdermal System) in Healthy Elderly and Non-Elderly Volunteers

Resource links provided by NLM:


Further study details as provided by Somerset Pharmaceuticals:

Primary Outcome Measures:
  • Dose Proportionality of PK parameters and EMSAM release characteristics. [ Time Frame: 33 days ]

Enrollment: 32
Study Start Date: April 2007
Study Completion Date: August 2007
Arms Assigned Interventions
Active Comparator: A
EMSAM 6mg
Drug: EMSAM (Selegiline Transdermal System) 6mg
STS 6mg/24hr
Active Comparator: B
EMSAM (Selegiline Transdermal System) 12mg
Drug: EMSAM (Selegiline Transdermal System) 12mg
EMSAm 12mg/24Hr

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or Female, 18 to 45years of age (inclusive) and 65 years of age or older.
  2. Non-obese as defined by being within 15% of desirable body weight for frame size (Appendix II).
  3. In general good health as ascertained by physical examination (PE) including measurement of supine and standing vital signs, medical history, clinical laboratory studies, and 12-lead electrocardiogram (ECG).
  4. Females must have a negative serum pregnancy test during screening confirmed by a negative urine pregnancy screen at the baseline visit. Women of childbearing potential must agree to continuously use a medically acceptable method of birth control during the course of the study. Acceptable birth control methods are hormonal contraceptives, intrauterine devices or double barrier method (a combination of condom plus contraceptive foam). Postmenopausal females will be eligible to participate if their last normal menses was at least one (1) year prior to study entry.
  5. Able and willing to provide informed consent.
  6. Able and willing to follow a modified diet.
  7. Able and willing to follow the requirements of the study; willing to wear a patch, no swimming, no excessive exercise, etc.

Exclusion Criteria:

  1. Presence of significant acute or chronic medical disorder that might complicate or interfere with MAO inhibitor therapy, such as:

    1. Any cardiovascular or cardiac condition requiring drug treatment. Upon review with Sponsor, subjects with well controlled hypertension or hyperlipidemia will be allowed.
    2. History of symptomatic orthostatic hypotension, or in the investigator's best clinicaljudgment a clinically significant postural decrease in systolic blood pressure at screening or baseline.
    3. Type I diabetes mellitus, or poorly controlled Type II diabetes mellitus.
    4. Malignancy and/or chemotherapy within 1 year prior to screening, other than basal cell carcinoma. Malignancies more than 1 year may not preclude participation and will be reviewed on a case-by-case basis by the Somerset Pharmaceuticals, Inc., medical monitor.
    5. Any skin condition (e.g., eczema, psoriasis, dyshydrosis) that might interfere with application and adherence of the STS.
    6. Known or suspected hypersensitivity to selegiline or other MAO inhibitors.
    7. Any significant immunological, pulmonary, hematologic, endocrine and/or metabolic disease or disorder or severe or acute medical illness, that is, metastatic cancer, brain tumors, decompensated cardiac, hepatic or renal failure.
    8. Neurological disorders including delirium, history of head trauma, movement disorders, dementia, multiple sclerosis, stroke, within the past 6 months preceding the study.
  2. Any central nervous system disorder including Alzheimer's disease, Parkinson's disease, epilepsy, or cerebrovascular disease.
  3. Any psychiatric disorders (except personality disorders).
  4. Any mood disorder including MDD which is current or relapsed over the past three years.
  5. ADHD.
  6. Any conditions that may cause depression including endocrinopathies other than diabetes, lymphoma, pancreatic cancer.
  7. Any other illness or disorder that in the opinion of the Investigator would place the subject at significant risk or any inability to follow the requirements of the study regarding maintaining scheduled visits or patch applications.
  8. Use of any medication listed below within five half-lives prior to baseline. A longer period of time may be specifically noted for certain medications as indicated:

    1. All contraindicated medications (see Section 7.1.4.3)
    2. Psychotropic medication, including centrally active anticholinergics, anticonvulsants, antiparkinsonian agents, fluoxetine (5 weeks), MAOIs (2 weeks), antipsychotics (oral - 60 days; intramuscular - 10 weeks), anxiolytics, vasodilators (exception: Viagra is permitted), cerebral enhancers (acetylcholinesterase inhibitors), psychostimulants, lithium carbonate, nootropics, reserpine, methyldopa (within 30 days), ergot preparations.
    3. Sympathomimetic drugs, e.g., amphetamines, methylphenidate, dopamine, epinephrine, norepinephrine, over-the-counter (OTC) and prescription nasal decongestants (with the exception of nasal steroids), oral or inhaled sympathomimetic bronchodilators (e.g., albuterol [Proventil], Serevent) and appetite suppressants.
    4. Any serotonergic drug including sumatriptan succinate (Imitrex), zolmitriptan (Zomig), cyproheptadine (Periactin), methysergide (Sansert) or other agonists or antagonists of serotonin receptors.
    5. Meperidine (Demerol), or other opioids.
    6. R(-)tryptophan, metoclopramide.
    7. St. John's wort / hypericum within two (2) weeks and other herbal supplements
    8. Dietary supplements containing tyramine and/or ephedrine.
  9. Presence of an Axis-II disorder that makes it unlikely that the subject will be compliant.
  10. Presence or history of bipolar disorder or psychotic disorder.
  11. Serious risk of suicide.
  12. History of substance abuse, including alcohol abuse as defined by DSM-IV criteria, within the past 12 months.
  13. Current use of tobacco products.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00532116

Locations
United States, Hawaii
Covance Clinical Research Unit
Honolulu, Hawaii, United States
Sponsors and Collaborators
Somerset Pharmaceuticals
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00532116     History of Changes
Other Study ID Numbers: S9303-P0601
Study First Received: September 18, 2007
Last Updated: September 18, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Somerset Pharmaceuticals:
Healthy
Elderly
Non Elderly
Healthy Volunteers

Additional relevant MeSH terms:
Selegiline
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Monoamine Oxidase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 28, 2014